middle.news
Avecho Completes Treatment Phase in Phase III Insomnia Trial Ahead of June Interim Readout
10:16am on Thursday 21st of May, 2026 AEST
•
Healthcare
Read Story
Avecho Completes Treatment Phase in Phase III Insomnia Trial Ahead of June Interim Readout
10:16am on Thursday 21st of May, 2026 AEST
Key Points
Treatment phase completed for 244 participants
Interim analysis results expected late June 2026
Trial supports TGA registration for OTC CBD insomnia treatment
Australian commercial rights licensed to Sandoz AG
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE